Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20598617 | 1.00 | CYP2D6 (0.47) | CYP2D6ALDH1A1MGLLOPRD1OPRK1 | |
| SCHEMBL20598278 | 1.00 | CYP2D6 (0.47) | CYP2D6ALDH1A1MGLLOPRD1OPRK1 | |
| SCHEMBL20598276 | 1.00 | CYP2D6 (0.47) | CYP2D6ALDH1A1MGLLOPRD1OPRK1 | |
| SCHEMBL18785464 | 1.00 | CYP2D6 (0.47) | CYP2D6ALDH1A1MGLLOPRD1OPRK1 | |
| SCHEMBL19096927 | 0.86 | ALDH1A1 (0.44) | CYP2D6ALDH1A1MGLLOPRK1CYP3A4 | |
| SCHEMBL17328227 | 0.86 | ALDH1A1 (0.44) | CYP2D6ALDH1A1MGLLOPRK1CYP3A4 | |
| SCHEMBL18785449 | 0.85 | CYP2D6 (0.51) | CYP2D6ALDH1A1MGLLOPRD1OPRK1 | |
| SCHEMBL20598279 | 0.85 | MEN1 (0.47) | ALDH1A1MGLLGPR119 | |
| SCHEMBL18785081 | 0.85 | MEN1 (0.47) | ALDH1A1MGLLGPR119 | |
| SCHEMBL20598448 | 0.85 | MEN1 (0.47) | ALDH1A1MGLLGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689398-B2 | OXA-Diazaspiro compounds having activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-23 | — | — | US | disclosed |
| US-10689398-B2 | OXA-Diazaspiro compounds having activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-23 | — | — | US | disclosed |
| US-20190002475-A1 | OXA-DIAZASPIRO COMPOUNDS HAVING ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
| US-20190002475-A1 | OXA-DIAZASPIRO COMPOUNDS HAVING ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
| WO-2017067664-A1 | OXA-DIAZASPIRO COMPOUNDS HAVING ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689398-B2 | OXA-Diazaspiro compounds having activity against pain | OPRD1, SIGMAR1, OPRK1 | CYP2D6 967/4885ALDH1A1 1315/4885MGLL 1738/4885 |
| US-20190002475-A1 | OXA-DIAZASPIRO COMPOUNDS HAVING ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | CYP2D6 967/4885ALDH1A1 1315/4885MGLL 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.